Dmitry Balyasny’s BioXcel Therapeutics BTAI Stock Holding History

Dmitry Balyasny’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,300	Closed	-$52.6K	–	2513
2023 Q3	$52.6K	Buy	+1,300	New	+$131K	﹤0.01%	2156

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dmitry Balyasny's BTAI Position: Q4 2023 in Review

Dmitry Balyasny sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 1,300 shares — an estimated $52.6K sold.

Dmitry Balyasny first reported a position in BTAI in Q3 2023 and held it in 1 quarter. The position peaked at $52.6K in Q3 2023. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

Dmitry Balyasny reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
Dmitry Balyasny sold 1,300 BioXcel Therapeutics shares in Q4 2023, an estimated $52.6K.
Dmitry Balyasny first reported a position in BioXcel Therapeutics in Q3 2023 and held it in 1 quarter.
Dmitry Balyasny's BioXcel Therapeutics position peaked at $52.6K in Q3 2023.
73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.